Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas

Arvinas’s ARV-471 Achieves Clinical Benefit Rate Of 38% In Breast Cancer Setting

By Vandana Singh
November 22, 12:20 PM
Arvinas Inc (NASDAQ:ARVN) announced initial results from the Phase 2 cohort expansion portion of a phase 1/2 study with ARV-471 in…

ARVN

Read More
1 minute read
  • Biotech
  • General
  • News

Applied UV Subsidiary Sterilumen Has Been Granted Canadian Patent Number 3127069 Titled “System For Neutralizing Pathogens On Tactile Surfaces” – Canadian Patent Database

By Benzinga Newsdesk
November 22, 12:17 PM
Patent 3127069 Summary - Canadian Patents Database (ic.gc.ca)

AUVI

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Merck’s Keytruda Phase 3 Trial Meets Primary Endpoint In Gastric Cancer Patients

By Vandana Singh
November 22, 10:55 AM
Merck & Co Inc (NYSE:MRK) has announced topline results from the pivotal Phase 3 KEYNOTE-859 trial of its flagship anti-PD-1 therapy,…

MRK

Read More
1 minute read
  • Biotech
  • Financing
  • General
  • Health Care
  • M&A
  • Movers
  • News
  • Offerings
  • Penny Stocks
  • Trading Ideas

Graybug Vision Agrees To Merge With Inflammatory Disease-Focused Biopharma

By Vandana Singh
November 22, 10:50 AM
Graybug Vision Inc (NASDAQ:GRAY) and CalciMedica Inc (CalciMedica) have announced a definitive merger agreement to combine the companies in an all-stock transaction. …

GRAY

Read More
1 minute read
  • FDA
  • News

Novartis Highlights Advances With Kisqali, Iptacopan, Scemblix And YTB323 Data At SABCS And Ash

By Benzinga Newsdesk
November 22, 10:28 AM
First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal hemoglobinaria (PNH), a rare and serious

NVS

Read More
5 minute read
  • FDA
  • News

Cel-Sci Corp Says Phase 3 Trial Showed Multikine Immunotherapy Extended Lives Of Patients With Locally Advanced Primary SCCHN

By Benzinga Newsdesk
November 22, 10:09 AM
CEL-SCI Corporation (NYSE:CVM) today issued a letter to its shareholders. Dear CEL-SCI Shareholders: I wanted to write to update you on our progress. Our story is following the well-worn path of all

CVM

Read More
4 minute read
  • Biotech
  • Commodities
  • Earnings
  • FDA
  • General
  • Guidance
  • Health Care
  • Large Cap
  • M&A
  • Management
  • Markets
  • Media
  • News
  • Small Cap
  • Tech
  • Top Stories

Jack Ma’s Ant Group Slapped With $1B Fine, Carl Icahn’s Huge Short Position In GameStop, Novavax Culls COVID-19 Vaccine Alliance With GAVI: Top Stories Tuesday, Nov. 22

By Vandana Singh
November 22, 10:00 AM
Reuters

AMZN

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • News

TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating Its Lead Compound, OmnImmune, In Patients With Acute Myeloid Leukemia

By Benzinga Newsdesk
November 22, 9:12 AM
3 Patients Dosed in 5 Patient Safety Cohort EDINBURGH, Scotland, Nov. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP)

TCBP

Read More
2 minute read
  • Biotech
  • Events
  • General
  • News

Lantern Pharma Announces Data Highlighting The Anti-Tumor Potency Of Drug Candidate LP-184 For Glioblastoma At The Society For Neuro-oncology Annual Meeting

By Benzinga Newsdesk
November 22, 9:08 AM
Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the

LTRN

Read More
3 minute read
  • Biotech
  • General

Arvinas Announces ARV-471 Achieved Clinical Benefit Rate Of 38% In Evaluable Patients And Continues To Show A Favorable Tolerability Profile In Its Phase 2 Expansion Trial

By Bill Haddad
November 22, 8:15 AM
ARV-471 continues to show activity in heavily pre-treated patients with locally advanced or metastatic ER+/HER2- breast cancer   Median progression free survival of 3.7 months in all patients and 5.7 months in

ARVN

Posts pagination

Previous 1 … 619 620 621 … 795 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service